All
1.
Activity ex vivo of cytotoxic drugs in patient samples of peritoneal carcinomatosis with special focus on colorectal cancer
Peter H Cashin, Haile Mahteme, Wilhelm Graf, Henning Karlsson, Rolf Larsson, Peter Nygren BMC Cancer 2013, 13 :435 (24 September 2013)
Abstract | Full text | PDF
| PubMed
2.
Exosome derived from epigallocatechin gallate treated breast cancer cells suppresses tumor growth by inhibiting tumor-associated macrophage infiltration and M2 polarization
Ji-Young Jang, Jong-Kuen Lee, Yoon-Kyung Jeon, Chul-Woo Kim BMC Cancer 2013, 13 :421 (17 September 2013)
Abstract | Full text | PDF
| PubMed
3.
Microspheres targeted with a mesothelin antibody and loaded with doxorubicin reduce tumor volume of human mesotheliomas in xenografts
Sherrill L Macura, Jeremy L Steinbacher, Maximilian B MacPherson, Melissa J Lathrop, Mutlay Sayan, Jedd M Hillegass, Stacie L Beuschel, Timothy N Perkins, Page C Spiess, Albert van der Vliet, Kelly J Butnor, Arti Shukla, Marilyn Wadsworth, Christopher C Landry, Brooke T Mossman BMC Cancer 2013, 13 :400 (11 September 2013)
Abstract | Full text | PDF
| ePUB | PubMed
|
Editor’s summary
Silica microparticles loaded with doxorubicin (DOX) and modified with a mesothelin specific antibody demonstrate higher effectiveness and lower toxicity than DOX systemic treatment in a mouse xenograft model of human peritoneal mesothelioma.
4.
Effectivity of pazopanib treatment in orthotopic models of human testicular germ cell tumors
Mercè Juliachs, August Vidal, Xavier del Muro, Josep M Piulats, Enric Condom, Oriol Casanovas, Mariona Graupera, Jose R Germà, Alberto Villanueva, Francesc Viñals BMC Cancer 2013, 13 :382 (10 August 2013)
Abstract | Full text | PDF
| ePUB | PubMed
5.
Combination of carbonic anhydrase inhibitor, acetazolamide, and sulforaphane, reduces the viability and growth of bronchial carcinoid cell lines
Reza Mokhtari, Sushil Kumar, Syed S Islam, Mehrdad Yazdanpanah, Khosrow Adeli, Ernest Cutz, Herman Yeger BMC Cancer 2013, 13 :378 (8 August 2013)
Abstract | Full text | PDF
| PubMed
6.
Screening for phenotype selective activity in multidrug resistant cells identifies a novel tubulin active agent insensitive to common forms of cancer drug resistance
Mårten Fryknäs, Joachim Gullbo, Xin Wang, Linda Rickardson, Malin Jarvius, Malin Wickström, Saadia Hassan, Claes Andersson, Mats Gustafsson, Gunnar Westman, Peter Nygren, Stig Linder, Rolf Larsson BMC Cancer 2013, 13 :374 (6 August 2013)
Abstract | Full text | PDF
| ePUB | PubMed
7.
Disruption of focal adhesion kinase and p53 interaction with small molecule compound R2 reactivated p53 and blocked tumor growth
Vita M Golubovskaya, Baotran Ho, Min Zheng, Andrew Magis, David Ostrov, Carl Morrison, William G Cance BMC Cancer 2013, 13 :342 (11 July 2013)
Abstract | Full text | PDF
| ePUB | PubMed
8.
Functional p53 is required for rapid restoration of daunorubicin-induced lesions of the spleen
Lars Herfindal, Lene Myhren, Bjørn Gjertsen, Stein Døskeland, Gro Gausdal BMC Cancer 2013, 13 :341 (11 July 2013)
Abstract | Full text | PDF
| ePUB | PubMed
9.
Sticky siRNAs targeting survivin and cyclin B1 exert an antitumoral effect on melanoma subcutaneous xenografts and lung metastases
Valerie Kedinger, Aline Meulle, Omar Zounib, Marie-Elise Bonnet, Jean-Baptiste Gossart, Elodie Benoit, Melanie Messmer, Pattabhiraman Shankaranarayanan, Jean-Paul Behr, Patrick Erbacher, Anne-Laure Bolcato-Bellemin BMC Cancer 2013, 13 :338 (9 July 2013)
Abstract | Full text | PDF
| ePUB | PubMed
10.
Anti-lymphangiogenic properties of mTOR inhibitors in head and neck squamous cell carcinoma experimental models
Oleksandr Ekshyyan, Tara N Moore-Medlin, Matthew C Raley, Kunal Sonavane, Xiaohua Rong, Michael A Brodt, Fleurette Abreo, Jonathan Alexander, Cherie-Ann O Nathan BMC Cancer 2013, 13 :320 (1 July 2013)
Abstract | Full text | PDF
| ePUB | PubMed
